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Fig. 1. Clinical manifestation of the 
skin lesions. (A) A tender dark ery-
thematous scaly indurated plaque 
with oozing on the right thigh. (B) 
A tender light brown, ill-defined 
induration with cigarette-paper-like 
fine scales on the right upper lateral 
arm. 
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Dear Editor:
Extranodal NK/T-cell lymphoma (ENTCL), nasal type, is a 
well-defined aggressive cytotoxic lymphoma1. Although 
immunophenotyping with CD56 is known to be positive 
in practically all cases, CD56-negative cases have also 
been reported, particularly in the upper respiratory tract. 
However, there are very few reports of skin involvement2. 
Here, we report a unique case of a CD56-negative, Ep-
stein-Barr virus (EBV)-positive ENTCL, nasal type, with cu-
taneous involvement. 
A 35-year-old Korean female patient presented with a ten-
der violaceous crusted indurated plaque on the right thigh 
and a light brown ill-defined induration on the right upper 
arm (Fig. 1). Histopathologic examination showed an atyp-
ical lymphocytic infiltration composed of small- to me-
dium-sized cells with irregular folded nuclei, and incon-
spicuous nucleoli. The infiltrate demonstrated angiocentric 
growth with frequent mitoses. Focal epidermal and dermal 
necrosis were also noted (Fig. 2A, B). The infiltrated cells 
stained positively for antibodies against surface CD3, 
CD8, and granzyme B, whereas they were negative 
against CD4, CD56, and CD20 (Fig. 2C∼E). EBV-encoded 
RNA (EBER) in situ hybridization was positive in many in-
filtrated cells (Fig. 2F). Three months before, the patient 
had been diagnosed with ENTCL, nasal type, for her re-
current nasopharyngeal ulcer. The microscopic evaluation 
of the uvula showed similar findings to that of the skin. 
Bone marrow biopsy, computed tomography and whole 
body 18-fluoro-2-deoxyglucose positron emission tomog-
raphy scan revealed no systemic invasion of the lympho-
ma. Despite cisplatin-based concurrent chemoradiation 
therapy, there was only a partial reduction of the tumor. 
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Fig. 2. Microphotograph of the 
lesion on the right thigh. (A) Dense 
cellular infiltrates involving the deep 
dermis. Angiocentricity is conspicu-
ous and epidermal necrosis is visible 
(H&E, ×12). (B) Atypical lympho-
cytes composed of small- to medi-
um-sized cells with irregular folded 
nuclei, inconspicuous nucleoli, and 
moderate, pale to clear cytoplasm 
demonstrating angiocentric growth 
and angiodestruction. Frequent mi-
toses are seen (H&E, ×400). (C) 
Positive immunohistochemical stai-
ning with surface CD3 in atypical 
lymphoid cells (×400). (D) CD20 
is not stained (×400). (E) CD56 is 
completely absent in the tumor 
(×400). (F) Epstein-Barr virus-enco-
ded RNA in situ hybridization 
showing many positive cells (×400).
ENTCL, nasal type, is a rare aggressive lymphoma that oc-
curs more commonly in East Asia. Patients are typically 
middle-aged adults and have a male predominance3. The 
prognosis is poor regardless of therapeutic strategies, with 
a median survival no more than 12 months. The skin is 
known to be the second most common site of involve-
ment and the disease usually manifests as multiple ulcer-
ated plaques or tumors on the trunk or extremities. Histo-
pathologically, ENTCL is characterized by dense infiltrates 
involving the dermis and often the subcutis. The cells 
have irregular or oval nuclei, moderately dense chroma-
tin, and a pale cytoplasm. Prominent angiocentricity and 
angiodestruction often accompany extensive necrosis1. 
Immunophenotypically, the neoplastic cells typically stain 
for antibodies against CD2, CD56, cytoplasmic CD3, and 
cytotoxic proteins (TIA-1, granzyme B, and perforin), but 
lack surface CD34. However, rare cases are CD56 neg-
ative, and they stain positively for surface CD3, CD5 and 
CD8. Detection of EBV and expression of cytotoxic pro-
teins are required for the diagnosis of these CD56-negative 
cases4. 
Most of the reported CD56-negative cases occurred in the 
upper respiratory tract5. Concerning skin involvement, to 
our knowledge, there have only been three cases recorded 
in the literature2. CD56-negative cases seem to be as ag-
gressive as CD56-positive cases, and are usually un-
responsive to conventional chemotherapy, with poor prog-
nosis and a short median survival2.
This case emphasizes that CD56 might not be invariably 
positive in ENTCL even in cases with extranasal cutaneous 
involvement. The immunohistochemistry and EBER in situ 
hybridization would be important ancillary studies for the 
accurate diagnosis of this rare aggressive cytotoxic lym-
phoma.
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Development of Vitiligo during Treatment 
with Adalimumab: A Plausible or Paradoxical Response?
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Dear Editor:
Adalimumab is a complete human monoclonal anti-tumor 
necrosis factor α (anti-TNFα) that is generally well tolera-
ted. With increasing use of adalimumab and other an-
ti-TNFα therapies, several cutaneous adverse events have 
been reported during the therapy, including immune-me-
diated skin lesions1. A 39-year-old woman who had an 
11-year history of Crohn’s disease and was treated with 
adalimumab (40 mg administered subcutaneously every 
other week) presented at our clinic with multiple achro-
mic macules and patches on the extremities (Fig. 1). The 
lesions developed abruptly about 12 months after the ini-
tiation of adalimumab therapy. The diagnosis of vitiligo 
was made after the patient’s skin turned blue under a 
Wood’s lamp. Laboratory tests were also performed to check 
for other autoimmune conditions, including thyroid dis-
orders, and no abnormality was diagnosed. The patient 
denied any family history of vitiligo. She has been treated 
with a combination therapy of excimer laser and topical 
tacrolimus without stopping the adalimumab therapy for 
about 1 year, and has shown minimal response thus far.
The role of anti-TNFα inhibitors in the development of vi-
tiligo is complicated and contradictory. There have been 
several case reports that showed improvement in vitiligo 
in patients receiving anti-TNFα therapy for other diseases2. 
The therapeutic effect of anti-TNFα inhibitors on vitiligo 
might result from stopping the physiological effect of 
TNFα on melanogenesis. Concretely, it has been reported 
that TNFα decreases the level of tyrosinase, a rate-limit-
ing enzyme in melanin biosynthesis in vitro3. The melano-
cytotoxic effect of TNFα in vitiligo has also been demon-
strated2. On the contrary, anti-TNFα inhibitors have been 
